Lifileucel (LN-144) for Melanoma

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, NY
MelanomaLifileucel (LN-144) - Biological
Eligibility
18+
All Sexes

Study Summary

This trial is testing a new cancer treatment for people with melanoma that has spread to the brain.

Eligible Conditions
  • Metastatic Melanoma

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1 year

1 year
Feasibility measured by the number of patients who undergo surgery and successfully undergo LN-144 infusion
Feasibility of treatment with LN-144 in patients with asymptomatic Metastatic Melanoma to the Brain (MMB)

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Lifileucel (LN-144)
1 of 2
Participants with Melanoma Brain Metastases
1 of 2

Experimental Treatment

10 Total Participants · 2 Treatment Groups

Primary Treatment: Lifileucel (LN-144) · No Placebo Group · Phase 1

Lifileucel (LN-144)
Biological
Experimental Group · 1 Intervention: Lifileucel (LN-144) · Intervention Types: Biological
Participants with Melanoma Brain Metastases
Biological
Experimental Group · 1 Intervention: Lifileucel (LN-144) · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,865 Previous Clinical Trials
591,634 Total Patients Enrolled
75 Trials studying Melanoma
15,944 Patients Enrolled for Melanoma
Iovance Biotherapeutics, Inc.Industry Sponsor
19 Previous Clinical Trials
1,725 Total Patients Enrolled
8 Trials studying Melanoma
950 Patients Enrolled for Melanoma
Allison Betof Warner, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Alexander Shoushtari, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
39 Total Patients Enrolled
3 Trials studying Melanoma
39 Patients Enrolled for Melanoma

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have healthy blood and organ function.

Frequently Asked Questions

Are there any open spots remaining in this study?

"Affirmative, according to the information present on clinicaltrials.gov this trial is actively searching for eligible applicants. It initially went live on November 25th 2022 and was updated most recently on the 28th of that same month. 10 patients need to be identified from 1 medical centre." - Anonymous Online Contributor

Unverified Answer

What is the approximate number of participants for this research project?

"Affirmative, clinicaltrials.gov data indicates that this research is in search of volunteers. This trial was first posted on November 25th 2022 and had its most recent update a few days later on the 28th. 10 participants are needed from one study centre for enrollment into the program." - Anonymous Online Contributor

Unverified Answer

Has Lifileucel (LN-144) obtained regulatory clearance from the FDA?

"Our analysis at Power has placed the safety of Lifileucel (LN-144) at 1, as this Phase 1 trial only carries a modicum of data backing its efficacy and security." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.